Dynavax Technologies' (DVAX) shareholder Deep Track Capital nominated four independent directors to the biopharmaceutical company's board to focus on key hepatitis B vaccine Heplisav and shift away from acquisitions.
"Focusing on Heplisav could result in nearly $2 billion of cash being returned to shareholders by the end of 2030," Deep Track Capital said Wednesday in a statement. The investment firm said it owns 13.53% of Dynavax.
A Deep Track letter to Dynavax shareholders criticized the biopharmaceutical company's board's "poor governance, reactive entrenchment maneuvers and unwillingness to work constructively."
Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel were nominated as Dynavax directors, Deep Track said.
Dynavax didn't immediately respond to a request for comment from MT Newswires.
Shares of the company rose 3.1% in recent trading.
Price: 13.33, Change: +0.40, Percent Change: +3.09
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。